Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - ... 7 - 8 - 9 - 10 - 11 - 12 - 13 - ...
UCB [BE0003739530/UCB]   
[18/10/2018]

UCB : UCB Media Room: World Osteoporosis Day

The impact of fragility fractures due to osteoporosis is being ignoredNew survey reveals that 61 per cent of women over 60 have little or no knowledge of osteoporosis, despite the fact that one in three is likely to develop a fragility fracture due to the conditionOver half 55 per cent of respondents believe that fragility fractures in older age are a result of an unlucky fall or accident, rather... See more
 
ECONOCOM GROUP [BE0974266950/ECONB]   
[18/10/2018]

ECONOCOM GROUP : ECONOCOM ENREGISTRE UNE BONNE DYNAMIQUE DE SON CHIFFRE D’AFFAIRES, EN CROISSANCE DE 13,5 % (DONT +6,0 % EN ORGANIQUE) SUR LES 9 PREMIERS MOIS DE L’ANNÉE 2018

Communiqué de presse – Information réglementée 18 octobre 2018  CHIFFRE D'AFFAIRES 9 MOIS 2018 Le groupe Econocom, acteur engagé de la transformation digitale, réalise sur les 9 premiers mois de 2018 un chiffre d'affaires de 1 944 millions d'euros en hausse de 13,5 % dont 6,0 % en organique. Toutes les activités du groupe sont en croissance organique sur la... See more
 
Gimv [BE0003699130/GIMB]   
[18/10/2018]

Gimv : Gimv acquires Medi-Markt Homecare Service and Medi Markt Service Nord Ost: market leadership in medical supplies to be further expanded after the merger

Gimv acquires MediMarkt Homecare Service and Medi Markt Service Nord Ost: market leadership in medical supplies to be further expanded after the merger As part of a succession plan, Gimv is investing in the two German companies MediMarkt Homecare Service GmbH and Medi Markt Service Nord Ost GmbH as well as a number of affiliated companies. These two leading... See more
 
UCB [BE0003739530/UCB]   
[18/10/2018]

UCB : UCB Media Room: Rozanolixizumab

UCB Accelerates AntiFcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development PhasePositive outcomes in proofofconcept study with subcutaneous rozanolixizumab in patients with myasthenia gravis MG: clinically meaningful improvement in multiple diseaserelated endpointsStrong 68% mean reduction of Serum IgG and IgG Autoantibodies observedSafety profile inline with subcutaneous dosing...